In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 137, Issue 2, 2007, Pages 109-116

  Beesley, Alex H ^a   Palmer, Misty Lee ^a,b   Ford, Jette ^a   Weller, Renae E ^a   Cummings, Aaron J ^a   Freitas, Joseph R ^a   Firth, Martin J ^a   Perera, Kanchana U ^a   De Klerk, Nicholas H ^a   Kees, Ursula R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

Acute lymphoblastic leukaemia; Clofarabine; Drug resistance; Flavopiridol; Nelarabine

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ASPARAGINASE; CLOFARABINE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; NELARABINE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL LINEAGE; CYTOTOXICITY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; T LYMPHOCYTE;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA, B-CELL, ACUTE; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, T-CELL, ACUTE; PIPERIDINES; TUMOR CELLS, CULTURED;

EID: 33947519478     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06527.x     Document Type: Article

References (47)

1. Avramis, V.I., Weinberg, K.I., Sato, J.K., Lenarsky, C., Willoughby, M.L., Coates, T.D., Ozkaynak, M.F. & Parkman, R. (1989) Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Research, 49, 241-247.
2. Beesley, A.H., Palmer, M.L., Ford, J., Weller, R.E., Cummings, A.J., Freitas, J.R., Firth, M.J., Perera, K.U., de Klerk, N. & Kees, U.R. (2006) Authenticity and drug resistance in a panel of acute lymphoblastic cell lines. British Journal of Cancer, 95, 1537-1544.
3. Berg, S.L., Blaney, S.M., Devidas, M., Lampkin, T.A., Murgo, A., Bernstein, M., Billett, A., Kurtzberg, J., Reaman, G., Gaynon, P., Whitlock, J., Krailo, M. & Harris, M.B. (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. Journal of Clinical Oncology, 23, 3376-3382.
4. Blagosklonny, M.V. (2004) Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle, 3, 1537-1542.
5. Byrd, J.C., Peterson, B.L., Gabrilove, J., Odenike, O.M., Grever, M.R., Rai, K. & Larson, R.A. (2005) Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clinical Cancer Research, 11, 4176-4181.
6. Cohen, M.H., Johnson, J.R., Massie, T., Sridhara, R., McGuinn, W.D., Jr, Abraham, S., Booth, B.P., Goheer, M.A., Morse, D., Chen, X.H., Chidambaram, N., Kenna, L., Gobburu, J.V., Justice, R. & Pazdur, R. (2006) Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clinical Cancer Research, 12, 5329-5335.
7. Curbo, S., Zhu, C., Johansson, M., Balzarini, J. & Karlsson, A. (2001) Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells. Biochemical and Biophysical Research Communications, 285, 40-45.
8. Demidenko, Z.N. & Blagosklonny, M.V. (2004) Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Research, 64, 3653-3660.
9. Estlin, E.J., Yule, S.M. & Lowis, S.P. (2001) Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide. Cancer Treatment Reviews, 27, 339-350.
10. Faderl, S., Gandhi, V., Keating, M.J., Jeha, S., Plunkett, W. & Kantarjian, H.M. (2005a) The role of clofarabine in hematologic and solid malignancies - development of a next-generation nucleoside analog. Cancer, 103, 1985-1995.
11. Faderl, S., Gandhi, V., O'Brien, S., Bonate, P., Cortes, J., Estey, E., Beran, M., Wierda, W., Garcia-Manero, G., Ferrajoli, A., Estrov, Z., Giles, F.J., Du, M., Kwari, M., Keating, M., Plunkett, W. & Kantarjian, H. (2005b) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood, 105, 940-947.
12. Flinn, I.W., Byrd, J.C., Bartlett, N., Kipps, T., Gribben, J., Thomas, D., Larson, R.A., Rai, K., Petric, R., Ramon-Suerez, J., Gabrilove, J. & Grever, M.R. (2005) Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leukemia Research, 29, 1253-1257.
13. Gandhi, V. & Plunkett, W. (2006) Clofarabine and nelarabine: two new purine nucleoside analogs. Current Opinion in Oncology, 18, 584-590.
14. Gandhi, V., Plunkett, W., Weller, S., Du, M., Ayres, M., Rodriguez, C.O., Jr, Ramakrishna, P., Rosner, G.L., Hodge, J.P., O'Brien, S. & Keating, M.J. (2001) Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. Journal of Clinical Oncology, 19, 2142-2152.
15. Gandhi, V., Kantarjian, H., Faderl, S., Bonate, P., Du, M., Ayres, M., Rios, M.B., Keating, M.J. & Plunkett, W. (2003) Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical Cancer Research, 9, 6335-6342.
16. Gandhi, V., Plunkett, W., Bonate, P.L., Du, M., Nowak, B., Lerner, S. & Keating, M.J. (2006a) Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clinical Cancer Research, 12, 4011-4017.
17. Gandhi, V., Keating, M.J., Bate, G. & Kirkpatrick, P. (2006b) Nelarabine. Nature Reviews Drug Discovery, 5, 17-18.
18. Jeha, S., Gandhi, V., Chan, K.W., McDonald, L., Ramirez, I., Madden, R., Rytting, M., Brandt, M., Keating, M., Plunkett, W. & Kantarjian, H. (2004) Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 103, 784-789.
19. Jeha, S., Gaynon, P.S., Razzouk, B.I., Franklin, J., Kadota, R., Shen, V., Luchtman-Jones, L., Rytting, M., Bomgaars, L.R., Rheingold, S., Ritchey, K., Albano, E., Arceci, R.J., Goldman, S., Griffin, T., Altman, A., Gordon, B., Steinherz, L., Weitman, S. & Steinherz, P. (2006) Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Journal of Clinical Oncology, 24, 1917-1923.
20. Karp, J.E., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., Garimella, T.S., Greer, J., Briel, J., Smith, B.D., Gore, S.D., Tidwell, M.L., Ross, D.D., Wright, J.J., Colevas, A.D. & Bauer, K.S. (2005) Phase I and Pharmacokinetic Study of Flavopiridol followed by 1-{beta}-D-Arabinofuranosylcytosine and Mitoxantrone in Relapsed and Refractory Adult Acute Leukemias. Clinical Cancer Research, 11, 8403-8412.
21. Kees, U.R., Ford, J., Price, P.J., Meyer, B.F. & Herrmann, R.P. (1987) PER-117: a new human ALL cell line with an immature thymic phenotype. Leukemia Research, 11, 489-498.
22. Kees, U.R., Ford, J., Dawson, V.M., Piall, E. & Aherne, G.W. (1989) Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines. Cancer Research, 49, 3015-3019.
23. Kees, U.R., Ford, J., Watson, M., Murch, A., Ringner, M., Walker, R.L. & Meltzer, P. (2003) Gene expression profiles in a panel of childhood leukemia cell lines mirror critical features of the disease. Molecular Cancer Therapeutics, 2, 671-677.
24. Kisor, D.F. (2005) Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias. Annals of Pharmacotherapy, 39, 1056-1063.
25. Kisor, D.F. (2006) Nelarabine use in leukemias. Drugs Today (Barc), 42, 455-465.
26. Kisor, D.F., Plunkett, W., Kurtzberg, J., Mitchell, B., Hodge, J.P., Ernst, T., Keating, M.J. & Gandhi, V. (2000) Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. Journal of Clinical Oncology, 18, 995-1003.
27. Kline, J.P. & Larson, R.A. (2005) Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert Opinion on Pharmacotherapy, 6, 2711-2718.
28. Kline, J. & Larson, R.A. (2006) Nelarabine in the treatment of refractory T-cell malignant diseases. Expert Opinion on Pharmacotherapy, 7, 1791-1799.
29. Kurtzberg, J., Ernst, T.J., Keating, M.J., Gandhi, V., Hodge, J.P., Kisor, D.F., Lager, J.J., Stephens, C., Levin, J., Krenitsky, T., Elion, G. & Mitchell, B.S. (2005) Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. Journal of Clinical Oncology, 23, 3396-3403.
30. Lambe, C.U., Averett, D.R., Paff, M.T., Reardon, J.E., Wilson, J.G. & Krenitsky, T.A. (1995) 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Research, 55, 3352-3356.
31. Lotfi, K., Mansson, E., Spasokoukotskaja, T., Pettersson, B., Liliemark, J., Peterson, C., Eriksson, S. & Albertioni, F. (1999) Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′- deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clinical Cancer Research, 5, 2438-2444.
32. Medh, R.D., Webb, M.S., Miller, A.L., Johnson, B.H., Fofanov, Y., Li, T., Wood, T.G., Luxon, B.A. & Thompson, E.B. (2003) Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics, 81, 543-555.
33. Nakanishi, T., Karp, J.E., Tan, M., Doyle, L.A., Peters, T., Yang, W., Wei, D. & Ross, D.D. (2003) Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clinical Cancer Research, 9, 3320-3328.
34. Newcomb, E.W. (2004) Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anti-Cancer Drugs, 15, 411-419.
35. Parker, B.W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M.D., Pommier, Y., Sausville, E.A. & Senderowicz, A.M. (1998) Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91, 458-465.
36. Pui, C.H. (2005) Quest for effective agents to combat T-cell acute lymphoblastic leukemia. European Journal of Cancer, 41, 1243-1245.
37. Pui, C.H., Relling, M.V. & Downing, J.R. (2004) Acute lymphoblastic leukemia. New England Journal of Medicine, 350, 1535-1548.
38. Pui, C.H., Jeha, S. & Kirkpatrick, P. (2005) Clofarabine. Nature reviews. Drug Discovery, 4, 369-370.
39. Rodriguez, C.O., Jr, Mitchell, B.S., Ayres, M., Eriksson, S. & Gandhi, V. (2002) Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Research, 62, 3100-3105.
40. Rodriguez, C.O., Jr, Stellrecht, C.M. & Gandhi, V. (2003) Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood, 102, 1842-1848.
41. Roecker, A.M., Allison, J.C. & Kisor, D.F. (2006) Nelarabine: efficacy in the treatment of clinical malignancies. Future Oncology, 2, 441-448.
42. Rudek, M.A., Bauer, K.S., Jr, Lush, R.M., III, Stinson, S.F., Senderowicz, A.M., Headlee, D.J., Arbuck, S.G., Cox, M.C., Murgo, A.J., Sausville, E.A. & Figg, W.D. (2003) Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Annals of Pharmacotherapy, 37, 1369-1374.
43. Senderowicz, A.M., Headlee, D., Stinson, S.F., Lush, R.M., Kalil, N., Villalba, L., Hill, K., Steinberg, S.M., Figg, W.D., Tompkins, A., Arbuck, S.G. & Sausville, E.A. (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. Journal of Clinical Oncology, 16, 2986-2999.
44. Shapiro, G.I., Supko, J.G., Patterson, A., Lynch, C., Lucca, J., Zacarola, P.F., Muzikansky, A., Wright, J.J., Lynch, T.J., Jr. & Rollins, B.J. (2001) A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clinical Cancer Research, 7, 1590-1599.
45. Thomas, J.P., Tutsch, K.D., Cleary, J.F., Bailey, H.H., Arzoomanian, R., Alberti, D., Simon, K., Feierabend, C., Binger, K., Marnocha, R., Dresen, A. & Wilding, G. (2002) Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology, 50, 465-472.
46. Waud, W.R., Schmid, S.M., Montgomery, J.A. & Secrist, J.A., III. (2000) Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides, Nucleotides and Nucleic Acids, 19, 447-460.
47. Whitlock, J.A., Krailo, M., Reid, J.M., Ruben, S.L., Ames, M.M., Owen, W. & Reaman, G. (2005) Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. Journal of Clinical Oncology, 23, 9179-9186.